Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence

The mechanistic target of rapamycin (mTOR) drives several physiologic and pathologic cellular processes and is frequently deregulated in different types of tumors, including glioblastoma (GBM). Despite recent advancements in understanding the molecular mechanisms involved in GBM biology, the surviva...

Descripción completa

Detalles Bibliográficos
Autores principales: Mecca, Carmen, Giambanco, Ileana, Donato, Rosario, Arcuri, Cataldo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312595/
https://www.ncbi.nlm.nih.gov/pubmed/30662577
http://dx.doi.org/10.1155/2018/9230479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312595/
https://www.ncbi.nlm.nih.gov/pubmed/30662577
http://dx.doi.org/10.1155/2018/9230479

Ejemplares similares